SCHEMBL4483520

SCHEMBL4483520

CCOC(=O)c1cc(-c2ccc(OCc3ccccc3)cc2)c[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.53
LMNA P02545 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MEN1 O00255 1/20 0.49
HSP90AA1 P07900 1/20 0.49
KMT2A Q03164 1/20 0.49
NR1H4 Q96RI1 1/20 0.49
ALDH1A1 P00352 1/20 0.49
JAK2 O60674 1/20 0.48
JAK3 P52333 1/20 0.48
GABRA1 P14867 1/20 0.48
GABRG2 P18507 1/20 0.48
GABRB3 P28472 1/20 0.48
GABRA5 P31644 1/20 0.48
GABRA3 P34903 1/20 0.48
GABRA2 P47869 1/20 0.48
MCL1 Q07820 2/20 0.48
MAOB P27338 2/20 0.47
DHODH Q02127 2/20 0.47
TRPM8 Q7Z2W7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27701346 0.88 ALDH1A1 (0.53) LMNAMEN1KMT2AALDH1A1MCL1
SCHEMBL1126817 0.85 GABRP (0.54) LMNAMEN1KMT2AALDH1A1JAK2
SCHEMBL5724654 0.82 LMNA (0.50) PPARGLMNAL3MBTL1NR1H4ALDH1A1
SCHEMBL4464289 0.81 CA12 (0.51) LMNAL3MBTL1MEN1KMT2AALDH1A1
SCHEMBL2771195 0.81 PPARG (0.57) PPARGLMNAL3MBTL1ALDH1A1MCL1
SCHEMBL7901147 0.79 MAPT (0.69) PPARGLMNAL3MBTL1MEN1HSP90AA1
SCHEMBL29544225 0.77 PPARG (0.52) PPARGLMNAL3MBTL1MEN1HSP90AA1
SCHEMBL10555646 0.77 PRMT5 (0.57) PPARGLMNAL3MBTL1MEN1HSP90AA1
SCHEMBL1126787 0.77 NOTUM (0.60) LMNAALDH1A1GABRA1GABRG2GABRB3
SCHEMBL340618 0.76 MAOB (0.67) PPARGLMNAL3MBTL1KMT2ANR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685125-B1 Pyrrole derivatives useful for the treatment of proliferative diseases MERCK PATENT GMBH (DE) 2012-06-06 EP disclosed
US-7598274-B2 N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors MERCK PATENT GMBH (DE) 2009-10-06 US disclosed
US-7598274-B2 N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors MERCK PATENT GMBH (DE) 2009-10-06 US disclosed
US-7598274-B2 N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors MERCK PATENT GMBH (DE) 2009-10-06 US disclosed
US-20070149594-A1 Pyrrole derivatives MERCK PATENT GMBH (DE) 2007-06-28 US disclosed
US-20070149594-A1 Pyrrole derivatives MERCK PATENT GMBH (DE) 2007-06-28 US disclosed
US-20070149594-A1 Pyrrole derivatives MERCK PATENT GMBH (DE) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149594-A1 Pyrrole derivatives RAF1, BRAF, ARAF PPARG 1058/4885LMNA 2851/4885L3MBTL1 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.